Inc.’s 2024 Female Founders list highlights why female founders are always a good bet
April 09, 2024 12:19 ET
|
Adyn, Inc.
Inc’s 2024 Female Founders list highlights why female founders are always a good bet. adyn founder, Elizabeth Ruzzo, is named to the list.
Cartesian Therapeutics Reports Full Year 2023 Financial Results and Provides Business Update
March 07, 2024 07:00 ET
|
Cartesian Therapeutics, Inc.
Topline data from Phase 2b study of Descartes-08, the Company’s potential first-in-class mRNA CAR-T cell therapy, in myasthenia gravis (MG) remains on track for mid-2024 On track to initiate Phase 2...
Comprise named top agency in several business, PR and marketing awards programs
December 19, 2023 06:00 ET
|
Comprise
Boulder, Colo., Dec. 19, 2023 (GLOBE NEWSWIRE) -- Comprise® solidified its status as a leading communications agency delivering integrated public relations and digital marketing services with the...
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: WaveDancer, Inc. (Nasdaq – WAVD), Selecta Biosciences, Inc. (Nasdaq – SELB), Graphite Bio, Inc. (Nasdaq – GRPH), CapStar Financial Holdings, Inc. (Nasdaq – CSTR)
November 16, 2023 10:42 ET
|
Brodsky & Smith LLC
BALA CYNWYD, Pa., Nov. 16, 2023 (GLOBE NEWSWIRE) -- Brodsky & Smith reminds investors of the following investigations. If you own shares and wish to discuss the investigation, contact Jason...
Selecta Biosciences Announces Merger with Cartesian Therapeutics
November 13, 2023 08:05 ET
|
Selecta Biosciences, Inc.
– Merger creates a fully integrated, publicly traded company pioneering RNA cell therapy for the treatment of autoimmune disease – – Cartesian’s wholly owned pipeline includes a Phase 2 lead asset,...
SHAREHOLDER ALERT: Kaskela Law LLC Announces Investigation of Selecta Biosciences, Inc. (NASDAQ: SELB) and Encourages Investors to Contact the Firm
November 11, 2023 08:26 ET
|
Kaskela Law
PHILADELPHIA, Nov. 11, 2023 (GLOBE NEWSWIRE) -- Kaskela Law LLC announces that it is investigating Selecta Biosciences, Inc. (NASDAQ: SELB) (“Selecta”) on behalf of the company’s investors. Since...
INVESTOR ALERT: Abbott Cooper PLLC Announces Investigation into Selecta Biosciences, Inc.; Urges Selecta Stockholders to Contact Abbott Cooper Regarding Their Legal Rights
November 03, 2023 00:27 ET
|
Abbott Cooper PLLC
Abbott Cooper PLLC Announces Investigation into Selecta Biosciences, Inc.
Selecta Announces Transition of Manufacturing and Clinical Operations of ImmTOR for SEL-212 to Commercialization Partner Sobi
October 31, 2023 16:03 ET
|
Selecta Biosciences, Inc.
WATERTOWN, Mass., Oct. 31, 2023 (GLOBE NEWSWIRE) -- Selecta Biosciences, Inc. (NASDAQ: SELB), a biotechnology company leveraging its clinically validated ImmTOR™ platform to develop tolerogenic...
Selecta Biosciences Reports Second Quarter 2023 Financial Results and Updates on Strategic Initiative Designed to Maximize Stockholder Value Associated with SEL-212 Economics
August 17, 2023 07:00 ET
|
Selecta Biosciences, Inc.
– Company to continue focusing on advancement of SEL-212, a potential treatment for chronic refractory gout; Biologics License Application (BLA) filing on track for 1H 2024 – – Company to...
Urea Cycle Disorders Treatment Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2017-2027
August 03, 2023 05:42 ET
|
ReportLinker
New York, Aug. 03, 2023 (GLOBE NEWSWIRE) -- Reportlinker.com announces the release of the report "Urea Cycle Disorders Treatment Market - Global Industry Size, Share, Trends, Opportunity, and...